Skip to main content
PLOS One logoLink to PLOS One
. 2022 Nov 23;17(11):e0277398. doi: 10.1371/journal.pone.0277398

Preliminary efficacy of cognitive-behavioral therapy on emotion regulation in adults with autism spectrum disorder: A pilot randomized waitlist-controlled study

Miho Kuroda 1,2,*, Yuki Kawakubo 1,*, Yoko Kamio 3, Hidenori Yamasue 4, Toshiaki Kono 5, Maiko Nonaka 1, Natsumi Matsuda 1, Muneko Kataoka 1, Akio Wakabayashi 6, Kazuhito Yokoyama 7, Yukiko Kano 1, Hitoshi Kuwabara 1,4,8,*
Editor: Tarek K Rajji9
PMCID: PMC9683545  PMID: 36417403

Abstract

Previous studies have demonstrated the clinical utility of cognitive-behavioral therapy in improving emotion regulation in children on the autism spectrum. However, no studies have elucidated the clinical utility of cognitive-behavioral therapy in improving emotion regulation in autistic adults. The aim of the present pilot study was to explore the preliminary clinical utility of a group-based cognitive-behavioral therapy program designed to address emotion regulation skills in autistic adults. We conducted a clinical trial based on a previously reported protocol; 31 participants were randomly allocated to the intervention group and 29 to the waitlist control group. The intervention group underwent an 8-week program of cognitive-behavioral therapy sessions. Two participants from the intervention group withdrew from the study, leaving 29 participants (93.5%) in the group. Compared with the waitlist group, the cognitive-behavioral therapy group exhibited significantly greater pre-to-post (Week 0–8) intervention score improvements on the attitude scale of the autism spectrum disorder knowledge and attitude quiz (t = 2.21, p = 0.03, d = 0.59) and the difficulty describing feelings scale of the 20-item Toronto Alexithymia Scale (t = -2.07, p = 0.04, d = -0.57) in addition to pre-to-follow-up (Week 0–16) score improvements on the emotion-oriented scale of the Coping Inventory for Stressful Situations (t = -2.14, p = 0.04, d = -0.59). Our study thus provides preliminary evidence of the efficacy of the group-based cognitive-behavioral therapy program on emotion regulation in autistic adults, thereby supporting further evaluation of the effectiveness of the cognitive-behavioral therapy program in the context of a larger randomized clinical trial. However, the modest and inconsistent effects underscore the importance of continued efforts to improve the cognitive-behavioral therapy program beyond current standards.

Introduction

Adults with autism spectrum disorder (ASD) frequently experience mental health problems, in addition to social communication impairments and repetitive and restricted behaviors as their core symptoms. Anxiety and depression are the most common comorbid symptoms of ASD [14]. Higher rates of anxiety and depression in autistic individuals have been associated with lower life satisfaction and greater social difficulties [5, 6]. However, the mechanisms underlying these high rates of comorbid anxiety and depression remain speculative. Studies have begun to focus on the potential importance of emotion regulation as a mental health risk factor in ASD [79].

Emotion regulation is generally defined as the automatic or intentional monitoring and modification of a person’s emotional state that promotes goal-directed behavior [10, 11]. Studies on emotion regulation in both autistic children and adults have primarily focused on differences in the implementation of a particular emotion regulation strategy, in addition to the relationship between particular emotion regulation and a range of outcomes, including mental health and social functioning [12, 13]. These studies have shown that, compared with typically developing (TD) participants, autistic individuals implement maladaptive emotion regulation strategies, such as emotion-oriented strategies, rather than adaptive emotion regulation strategies, such as task-oriented strategies [9, 14].

An important research focus linked to emotion regulation in ASD is to identify factors that lead to emotion regulation difficulties. Among the many frameworks for conceptualizing emotion regulation, the process model, which describes emotion regulation as a multicomponent and dynamic process between the individual and their context, is the most influential and widely known. This model distinguishes three stages of emotion regulation: identification (whether to regulate or not), selection (deciding which strategy to select), and implementation (implementing a strategy) [15]. In the identification stage, the process model emphasizes the importance of alexithymia, which refers to difficulty in identifying and labeling one’s own emotions; empirical studies have indicated increased levels of alexithymia in autistic individuals compared with TD individuals [9, 16]. With regard to the selection stage, the process model suggests that emotion regulation involves adopting an alternative point of view on emotional appraisals; these strategies require abilities which are impaired in ASD, such as theory of mind [15, 17]. Previous studies have suggested that theory of mind, i.e., the ability to attribute mental states to others to make sense of their behavior, is atypical in ASD [18, 19]. However, it remains unknown whether a universal pattern of cognitive impairment in ASD exists and whether multiple cognitive impairments are needed to explain its full range of behavioral symptoms [20]. Social cognition clearly encompasses a range of processes, including, but not limited to, theory of mind and emotion processing, which appear to be distinct but interdependent [21]. Studies of autistic individuals as well as studies of TD individuals both suggest that the skills involved in comprehending the self and others are interrelated and play an important role in emotion regulation [14, 22].

Previous studies have demonstrated the effectiveness of cognitive-behavioral therapy (CBT) in improving anxiety [2326], anger [27], and emotion regulation [2830] in autistic children and adolescents. However, few studies have investigated its efficacy in autistic adults and only one randomized controlled trial has assessed the effectiveness of CBT in alleviating obsessive-compulsive disorder (OCD) symptoms in autistic adults [31]. To our knowledge, no studies have elucidated the effectiveness of CBT in improving emotion regulation in autistic adults.

Usually, parents are involved in their child’s CBT sessions [29, 30]. As such, parents gain a greater understanding of ASD and help guide emotion regulation training in light of ASD traits. However, unlike in children, autistic adults need to better understand their own strengths and weaknesses, as they are expected to modify their own emotional regulation skills without their parents’ help. In addition, an ASD diagnosis can have adverse effects on emotions, including stigmatization and lowered self-esteem; however, having accurate knowledge of and a positive attitude towards an ASD diagnosis can foster self-awareness in a way that is matched with minimal self-criticism [32].

The aim of the present pilot study was to explore the preliminary efficacy of CBT on emotion regulation in autistic adults [33]. To this end, we conducted a group-based CBT program for emotion regulation in conjunction with psychoeducation about ASD to help autistic adults (1) acquire effective emotion regulation strategies, (2) increase their own emotional awareness, (3) improve their capacity to comprehend others’ emotions, and (4) increase their knowledge and improve their attitudes concerning ASD.

Materials and methods

Study design

We conducted a randomized controlled trial based on a previously reported protocol [33]. We used a single-blinded trial design in which the assessors did not attend the intervention sessions and did not know of the participants’ group assignments. We used a waitlist (WL) control group consisting of autistic individuals who received their usual services. After the study, participants in the WL control group had the option to receive the CBT program.

The trial was registered in the University Hospital Medical Information Network Clinical Trials Registry and was approved by the International Committee of Medical Journal Editors (No. UMIN000006236).

Ethical considerations

The study design was reviewed and approved by the institutional review board of The University of Tokyo Hospital (No. 2702) and the National Institute of Mental Health (No. A2010-022). All procedures were performed in accordance with the principles of the Declaration of Helsinki. All participants provided written informed consent after receiving a complete explanation of the trial.

Participants and randomization

Participants were individuals diagnosed with ASD. They were recruited through pools of research volunteers at two sites, the Department of Child Psychiatry, University of Tokyo Hospital (Site 1) and the Department of Child and Adolescent Mental Health, National Institute of Mental Health in Tokyo (Site 2). Recruitment information was advertised on the University of Tokyo Hospital’s website.

Participants were required to meet six inclusion criteria. (1) Participants were required to have a confirmed diagnosis of a pervasive developmental disorder (i.e., autistic disorder, Asperger’s disorder, or pervasive developmental disorder not otherwise specified) according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) [34]. This diagnostic confirmation was to be based on the Autism Diagnostic Schedule (ADOS) [35]; the Autism Diagnostic Interview, Revised (ADI-R) [36]; the Autism-Spectrum Quotient (AQ), Japanese version [37]; the Social Responsiveness Scale for Adults, Japanese version (SRS-A) [38]; the Social Communication Questionnaire, Japanese version (SCQ) [39]; or the Empathizing-Systemizing Quotient, Japanese version (ESQ) [40]. (2) Participants were required to be between 18 and 50 years old. (3) Participants were required to have a full intelligence quotient (FIQ) of at least 85 and a verbal intelligence quotient (VIQ) of at least 100, as assessed by the Wechsler Adult Intelligence Scale, Third Edition [41]. (4) Participants had to have graduated from high school. (5) Participants had to be aware of their ASD diagnosis. (6) Participants needed to have an awareness of their lack of emotional self-awareness and their poor comprehension of the emotions of others. Participants’ awareness of their lack of emotional self-awareness and poor comprehension of others’ emotions was confirmed through a direct interview with a PhD-qualified psychologist. The exclusion criterion was unstable comorbid mental disorder symptoms evaluated using the Mini-International Neuropsychiatric Interview [42] and diagnosed according to the DSM-IV-TR [34].

Participants were randomly allocated to groups through the University Hospital Clinical Trial Alliance Clinical Research Supporting System (UHCT ACReSS) with sex as the allocation factor. To achieve blinded allocations, the UHCT ACReSS provided a random allocation sequence such that the researchers and staff were unaware of it until after the enrollment period.

The pre-intervention assessments were completed at sites 1 and 2. The post-intervention and follow-up (FU) assessments were completed at Site 1. Blinded assessors conducted pre-intervention assessments within four weeks of the start of the interventions (Week 0) and post-intervention assessments within four weeks from the end of the interventions (Week 8), and FU assessments 8–12 weeks later (Week 16) (Fig 1).

Fig 1. CONSORT flow diagram.

Fig 1

Similar numbers of participants were allocated to the CBT and WL groups. Assessments were performed within four weeks prior to the start of the CBT/waiting period (pre-intervention), within four weeks after the conclusion of CBT/waiting period (post-intervention), and 12 weeks thereafter (follow-up). Abbreviations: CBT, cognitive-behavioral therapy; WL, waitlist.

We used G*Power statistical software [43] to estimate the target number of participants. The CBT program for emotion regulation in autistic children [30] had a significant clinical impact and hence powered this study to detect a large effect (Cohen’s d = 0.80). A significance level (p-value) of 0.05 (two-tailed), a test power of 0.8, and a layout proportion of 1 yielded an estimated requirement of 52 participants. Therefore, we used a sample size of 60 to account for potential dropouts.

Intervention

The CBT program we implemented was a group-based intervention that targeted emotion regulation improvements in autistic adults. Each CBT session lasted approximately 100 minutes, with weekly sessions that took place over an eight-week period. If a participant could not attend a group session, a supplementary individual session was offered up to three times. Two therapists and 4–5 participants formed each CBT group. The group leader was a certified, PhD-qualified psychologist with over 10 years’ experience assisting ASD clients. The sub-leader was a psychologist with a master’s degree.

We developed manuals for the CBT program on emotion regulation and psychoeducation about ASD for autistic adults with references to previous CBT studies. Each CBT session included a psychoeducation part on ASD (except for sessions 2, 7, and 8, which were dedicated to emotion regulation only) and an emotion regulation part (except for session 1, which was dedicated to psychoeducation on ASD). There was a short relaxation period between the two parts in each session (Table 1).

Table 1. Overview of the CBT program.

Duration Content
5 min Greeting and checking current emotion
30 min Session 1. Diagnosis and epidemiology of ASD
Session 2. How to relax
Session 3. Making a book of my favorite things
Session 4. My unique points compared with others
Session 5. My strengths
Session 6. My weakness and how to deal with them
Session 7. Study of anger
Session 8. Assertion
10 min Relaxation (deep breathing and light physical exercises)
40 min Session 1. Characterization of ASD
Session 2. Joy
Session 3. Safety
Session 4. Affection
Session 5. Anxiety
Session 6. How to reduce anxiety
Session 7. How to reduce anger
Session 8. Coping skill
5 min Rest period

Abbreviations: CBT, cognitive-behavioral therapy; ASD, autism spectrum disorder.

The materials for the ASD psychoeducation, including an original handout, were developed to help participants learn about and understand the nature of ASD. During the psychoeducation part, the group leader presented a lecture about diagnostic criteria, symptoms, etiology, and daily life. Participants were asked to explain their preferences, strengths, and weaknesses verbally, and a group discussion was held.

In the emotion regulation part, the interventions started with emotion education (such as recognizing and labeling emotions in self and others) in a concrete manner such that ASD participants could comprehend and externalize their emotions. The Cat-kit Japanese version [44] was used for the emotion regulation part of the CBT program to complement the weaknesses inherent to ASD. Based on randomized controlled trials which investigated CBT’s efficacy in improving emotional symptoms in autistic children and adolescents [23, 27], the Cat-kit was developed [45] to help autistic individuals become aware of how their thoughts, feelings, and actions interact, and how to use various visual tools to share their insights with others. Subsequently, the sessions progressed to cognitive reconstructions using more complex skills, based on relaxation and/or planned systematic exposure. Finally, problem solving skills, such as assertion skills and coping skills, were explained and discussed with the group. These interventions were applied across multiple emotions with a focus on learning and practicing various adaptive emotion regulation strategies.

Outcome measures

Primary outcomes

To determine the direct effects of the CBT intervention, we assessed the effects of changed intervention periods on the scores of the Coping Inventory for Stressful Situations, Japanese version (CISS) [46], the 20-item Toronto Alexithymia Scale Japanese version (TAS20) [47], the Motion Picture Mind-Reading task (MPMR) [48], and the ASD knowledge and attitude quiz (ASD-Q) (S2 File).

The CISS, a 48-item self-reported questionnaire, is used to determine an individual’s preferred emotion regulation strategies. It features subscales for task-oriented (CISS-T), emotion-oriented (CISS-E), and avoidance-oriented (CISS-A) coping styles. CISS-T assesses emotion regulation strategies such as cognitive reappraisal, CISS-E assesses emotion regulation strategies such as self-blaming, and CISS-A assesses emotion regulation strategies such as engaging in alternative activities. Each item is rated from 1 (“not at all”) to 5 (“very much”), and total scores for each subscale range from 16 to 80. Higher scores on the CISS-T indicate more adaptive strategies with sufficient emotion regulation. Higher scores on the CISS-E indicate more maladaptive strategies with difficulties in emotion regulation. Higher scores on the CISS-A indicate both adaptive and maladaptive strategies [9, 49].

The TAS20, which assesses own emotional awareness, is frequently used to measure alexithymia. Individuals with alexithymia have trouble identifying and describing their emotions, and tend to focus attention outside themselves. This self-reported assessment features seven questions about difficulties in identifying feelings (TAS20-F1), five questions about difficulties in describing feelings (TAS20-F2), and eight questions about externally oriented thinking (TAS20-F3). Each item is answered on a 5-point Likert-type scale. Total scores (TAS20-total) range from 20 to 100, and higher scores indicate more severe alexithymia.

The MPMR [48] assesses the capacity to comprehend others’ emotions and tests “theory of mind” abilities by means of a task that requires participants to assess whether certain emotion words suitably describe people in video clips from a television drama (Shiroi Kyotō). This task includes 41 video clips, each lasting 3–11 seconds, with concurrent auditory and visual presentations. The correct response percentage represents the task performance.

The ASD-Q is a self-report questionnaire developed specifically for this study that was used to assess knowledge and attitudes regarding ASD [33]. The ASD-Q comprises ten knowledge-based questions and five attitude-based questions about ASD. Each knowledge-based question has three response options (“true,” “false,” or “do not know”). The score is calculated according to the number of correct answers. The highest possible score is 10, and higher scores indicate greater knowledge of ASD. Each attitude-based question is answered on a 5-point Likert-type scale. The highest possible score is 25, and higher scores indicate a more positive attitude towards ASD.

Secondary outcomes

Secondary outcome measures included scores from the CISS, TAS20, MPMR, and ASD-Q at the 12-week FU assessment.

We speculated that participants would show greater adaptation and experience an improvement in anxiety and depressive symptoms due to their improved emotion regulation. Therefore, secondary outcomes included scores on the Global Assessment of Functioning (GAF), the 26-item World Health Organization Quality of Life scale (QOL) [50], the Liebowitz Social Anxiety Scale (LSAS) [51], the State-Trait Anxiety Inventory (STAI) [52], the Social Phobia and Anxiety Inventory (SPAI) [53], and the Center for Epidemiologic Studies Depression Scale (CES-D) [54]. The GAF and LSAS are clinician-reported measures, and the others are self-reported measures. Given the trial’s single-blinded nature, raters who were blinded to group assignments conducted the clinician-reported assessments.

Statistical analyses

The analyses were performed according to the intention-to-treat (ITT) principle. The ITT analysis of the results in this study was based on the initial treatment assignment, but not on the treatment eventually received.

Changes between pre-intervention and the post-intervention assessments were herein referred to as intervention period changes, and changes between pre-intervention and FU assessments were referred to as study period changes. We used independent t-tests (two-tailed) to compare the intervention or study period score changes between the CBT and WL groups. We used a p value of 0.05 as the significance threshold. The effect sizes were assessed using Cohen’s d. Statistical analyses were performed using SPSS 20 J (IBM, Armonk, NY).

Results

Recruitment and participant flow

Participant registration began on September 1, 2011, and the FU period ended on June 22, 2013.

We recruited 82 autistic individuals and assessed them based on the inclusion criteria. Of the 82, 60 (73.2%) met the inclusion criteria. We obtained informed consent and then enrolled the eligible participants in the trial through the UHCT ACReSS at the University of Tokyo.

Of the 60 included participants, 29 (21 men and eight women; mean age: 29.6 ± 8.0 years) and 31 (20 men and 11 women; mean age: 32.7 ± 8.1 years) were allocated to the WL control group and the CBT group, respectively. Two participants in the CBT group (one man and one woman) withdrew from the study (the woman was too busy, and the man lost his motivation to continue), yielding a final total of 29 participants (19 men and 10 women; mean age: 29.6 ± 8.0 years) in the CBT group (Fig 1).

The mean attendance rates in the 31 CBT participants were 80.5% for the group sessions alone and 92.5% when additional individual sessions were counted. Eight participants had a 100% group session attendance rate.

Baseline comparability of characteristics

Table 2 demonstrates that the CBT and WL groups were matched on a range of demographic variables (Table 2).

Table 2. Descriptive statistics of participant characteristics.

CBT WL
N 31 29
Male/female 20/11 21/8
DSM-IV subtype: Au/Asp/Nos 20/2/9 20/2/7
Comorbid disorder/no comorbid disorder 18/13 14/15
Medication/no medication 21/10 18/11
Mean (SD) Mean (SD)
Age, years 32.7 (8.1) 29.6 (8.0)
IQ Full 110.2 (12.9) 104.9 (11.9)
Verbal 114.8 (14.7) 109.2 (9.6)
Performance 102.6 (15.1) 98.0 (15.4)
ADOS Communication 3.2 (1.3) 3.4 (1.2)
Social interaction 7.0 (1.6) 7.3 (1.9)
ADI-R Social interaction 12.0 (6.2) 12.2 (5.7)
Communication 9.7 (5.0) 8.8 (4.2)
Restricted interest 3.3 (1.9) 3.3 (1.7)

Respondents were parents. CBT group, N = 23, WL group, N = 22.

Abbreviations: CBT, cognitive-behavioral therapy; WL, waitlist; DSM-IV, Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition; Au, autistic disorder; Asp, Asperger’s disorder; Nos, pervasive developmental disorder not otherwise specified; IQ, intelligence quotient; ADOS, Autism Diagnostic Schedule; ADI-R, Autism Diagnostic Interview, Revised.

Primary outcomes

The results for all outcome measures are presented in Table 3. We found no significant differences in pre-intervention assessments in the CISS-T and CISS-E scores, ASD-Q knowledge scores, TAS20-F1, TAS20-F2, TAS20-F3, and TAS20 total scores, and MPMR scores between the CBT and WL groups. The CISS-A score was the only exception.

Table 3. Comparisons of outcome measures for CBT and waitlist groups at pre-intervention (pre), post-intervention (post), and follow-up (FU).

Outcome measures CBT WL p-value
Cohen’s d
N = 31 N = 29 Pre Intervention period changes Study period changes
Pre Post FU Pre Post FU
CISS T Mean 49.5 52.2 51.6 51.1 49.7 52.3 0.95 0.07 0.83
SD 10.2 10.3 9.6 12.9 14.1 15.6 -0.02 0.53 0.06
E Mean 52.9 50.0 47.9 50.8 50.9 50.1 0.44 0.19 0.04*
SD 11.3 11.0 11.8 10.1 10.4 10.7 0.21 -0.37 -0.59
A Mean 42.9 43.2 44.0 36.4 35.2 35.0 0.01* 0.57 0.54
SD 10.1 9.3 12.3 10.8 11.0 9.1 0.77 0.16 0.17
TAS20 F1 Mean 22.9 21.3 21.0 23.1 23.2 23.6 0.59 0.20 0.14
SD 6.5 7.1 7.0 6.0 7.2 7.2 -0.14 -0.36 -0.40
F2 Mean 18.4 17.4 17.0 19.7 20.2 19.3 0.08 0.04* 0.42
SD 3.9 3.6 4.1 3.3 3.5 3.7 -0.47 -0.57 -0.22
F3 Mean 21.5 19.7 20.5 20.4 19.7 20.5 0.52 0.23 0.44
SD 5.1 4.0 4.5 4.1 3.3 4.1 0.17 -0.33 -0.21
Total Mean 65.0 63.7 62.1 66.7 67.3 67.4 0.24 0.30 0.19
SD 8.4 10.4 11.8 9.0 9.3 10.2 -0.31 -0.29 -0.36
MPMR Mean 69.7 77.3 79.9 66.3 70.9 72.2 0.36 0.36 0.30
SD 14.5 12.5 9.7 15.8 16.2 15.4 0.24 0.25 0.28
ASD-Q Knowledge Mean 7.8 8.6 8.4 7.6 8.0 8.2 0.60 0.42 0.88
SD 1.8 1.6 1.5 2.3 2.0 1.8 0.14 0.21 0.04
Attitude Mean 18.2 19.4 19.0 18.9 18.3 18.8 0.59 0.03* 0.20
SD 3.2 3.7 3.1 3.6 4.7 3.8 -0.14 0.59 0.34
GAF Mean 44.5 52.3 56.3 44.1 47.8 50.7 0.83 0.08 0.05
SD 8.8 8.3 8.4 7.9 8.0 6.8 0.06 0.48 0.53
QOL Mean 3.0 3.2 3.0 2.7 2.7 2.7 0.01* 0.53 0.69
SD 0.6 0.6 0.7 0.6 0.8 0.7 0.50 0.17 -0.11
LSAS Fear Mean 31.1 26.8 24.1 33.9 33.7 32.8 0.33 0.15 0.06
SD 15.0 11.5 14.2 13.8 12.0 12.8 -0.26 -0.39 -0.51
Avoidance Mean 23.2 21.0 19.5 26.0 29.3 27.9 0.29 0.06 0.07
SD 13.8 11.6 14.0 11.8 15.5 14.1 -0.27 -0.52 -0.50
STAI State Mean 47.6 46.1 49.3 54.8 53.6 52.8 0.06 0.90 0.38
SD 14.2 11.0 14.8 11.9 12.4 14.0 -0.50 -0.04 0.24
Trait Mean 57.4 53.5 53.8 62.2 59.9 57.1 0.10 0.49 0.80
SD 12.6 12.8 13.2 9.4 11.6 10.9 -0.43 -0.19 0.07
SPAI Social phobia Mean 114.0 107.9 100.1 132.2 128.4 127.8 0.03* 0.68 0.16
SD 43.3 37.9 44.6 29.7 36.6 38.3 -0.59 -0.11 -0.38
Agoraphobia Mean 26.3 24.5 23.0 27.4 27.4 26.1 0.79 0.52 0.32
SD 15.1 14.0 15.7 14.0 17.6 19.0 -0.07 -0.18 -0.27
CES-D Mean 23.6 19.3 22.8 28.9 26.6 25.1 0.11 0.42 0.45
SD 12.9 10.7 10.8 12.9 14.7 13.8 -0.42 -0.23 0.21

Abbreviations: CBT, cognitive-behavioral therapy; WL, waitlist; Pre, pre-intervention; Post, post-intervention; FU, follow-up; CISS, the Coping Inventory for Stressful Situations; T, Task-oriented; E, Emotion-oriented; A, Avoidance-oriented; ASD-Q, autism spectrum disorder questionnaire; TAS20, 20-item Toronto Alexithymia Scale; F1, Difficulty Identifying Feelings Subscale; F2, Difficulty Describing Feelings Subscale; F3, Externally Oriented Thinking Subscale; MPMR, the Motion Picture Mind-Reading task; GAF, Global Assessment of Functioning; QOL, 26-item World Health Organization Quality of Life scale; LSAS, Liebowitz Social Anxiety Scale; SPAI, Social Phobia and Anxiety Inventory; STAI, State-Trait Anxiety Inventory; CES-D, Center for Epidemiological Studies Depression Scale.

Significance:

* = p < 0.05.

The independent t-tests showed significant between-group differences in intervention period changes in the TAS20-F2 scores (t = -2.07, p = 0.04, d = -0.57) and the ASD-Q attitude scores (t = 2.21, p = 0.03, d = 0.59). This being said, these findings did not withstand the Bonferroni correction for multiple comparisons for the 10 primary outcome measures (p < 0.05/10). We found no significant between-group differences in intervention period changes in the CISS-T, CISS-E, and CISS-A scores, the ASD-Q knowledge scores, the TAS20-F1, TAS20-F3, and TAS20 total scores, and the MPMR scores.

Secondary outcomes

Results for all outcome measures are presented in Table 3. We found no significant differences in pre-intervention assessments in the GAF, QOL, LSAS, STAI, SPAI, and CES-D scores between the CBT and WL groups, except for the QOL and SPAI social phobia scores.

In the study period changes in secondary outcomes, independent t-test showed significant between-group differences in the CISS-E scores (t = -2.14, p = 0.04, d = -0.59). With regard to the CISS-T, CISS-A, ASD-Q knowledge and attitude scores, TAS20-F1, TAS20-F2, TAS20-F3, TAS20 total scores, and MPMR scores, we found no significant between-group differences in study period changes.

For other secondary outcomes, including the GAF, QOL, LSAS, STAI, SPAI, and CES-D scores, we found no significant between-group differences in either intervention period changes or study period changes.

Additionally, we conducted a repeated measure analysis of variance to explore time changes in the three outcomes over time, which showed significant results in the t-tests (i.e., TAS20-F2, ASD-Q attitude, and CISS-E). Specifically, treatment group (i.e., the CBT vs WL control group) was considered as the between-subjects factor, while time point (i.e., pre-intervention, post-intervention, and FU) was considered as the within-subjects factor. With respect to the TAS20-F2 scores, a significant effect of treatment group was found (F = 5.81, p = 0.019), whereas we did not observe a main effect of time (F = 1.33, p = 0.27) or a group-by-time interaction (F = 1.57, p = 0.22). With regards to the ASD-Q attitude scores, a group-by-time interaction and a main effect of treatment group or time were not seen (F = 3.03, p = 0.05; F = 0.05, p = 0.82; F = 0.65, p = 0.52, respectively). Finally, with respect to the CISS-E, a significant effect of time was found (F = 4.69, p = 0.02), whereas we did not observe a group-by-time interaction (F = 3.23, p = 0.05) or a main effect of treatment group (F = 0.03, p = 0.86).

Discussion

We found that group-based CBT on emotion regulation for autistic adults improved participants’ attitude towards ASD, their difficulties in describing feelings, and their maladaptive emotion regulation strategies. Moreover, we demonstrated an acceptable adherence to a current CBT intervention program.

Participants in the two groups significantly differed in their intervention period score change in the TAS20 difficulties in describing feelings scale. However, the post-intervention total TAS20 score in the CBT group remained high, and participants in this group were still classified as having a severe impairment (a score of 61–100) [55]. Therefore, the CBT program had a measurable effect on describing feelings but was still insufficient to alleviate alexithymia generally.

Previous studies have reported that psychoeducation helped autistic children [56] and families with autistic adults [57] develop more positive outlooks towards ASD. Our results were consistent with those studies; however, while positive changes in attitude towards ASD were observed immediately after the intervention, they were not sustained 12 weeks later, indicating that the clinical utility of our CBT program on positive attitude towards ASD remained limited.

The reduction in maladaptive strategies suggests that the CBT program improved emotion regulation. Furthermore, improvements at the FU assessment might reflect continued post-intervention success in emotion regulation in daily life. However, the present data were insufficient to clarify the mechanisms underlying the delay in this effect on emotion regulation. Emotion regulation studies in adults have demonstrated that autistic adults use less task-oriented strategies but more emotion-oriented strategies than TD adults [9, 14]. Although the current CBT program seems meaningful for reducing maladaptive strategies such as emotion-oriented strategies, future studies should aim to increase adaptive strategies, such as task-oriented strategies. We detected no significant changes in the MPMR scores over the intervention period. We speculated that alexithymia in ASD is related to deficits in the “theory of mind” based on previous studies [14, 22] and hypothesized that the ASD-focused CBT program would improve the ability to comprehend others’ emotions through the identification of one’s own emotions, or vice versa. However, our present findings do not support this hypothesis. Since the correct response rate increased in both groups, task repetition might have improved scores.

The secondary outcomes, which were used to assess the effects of the CBT program on adaptation, anxiety symptoms, and depression symptoms, did not significantly differ between the CBT and WL groups. Emotion regulation has been used to predict the symptoms of anxiety and depression in ASD [12, 13], and these emotional symptoms can be used to predict the adaptation of autistic individuals [5, 6]. However, the present CBT program, which showed effects on emotion regulation, did not reduce the emotional symptoms or improve adaptations. These negative results might be attributable to the relatively short-term intervention and study periods. Hence, future studies should elucidate the long-term effects of this intervention program, including the effects on adaptation and emotional symptoms and the improvements in emotion regulation brought on by the CBT program.

The initial power calculation proved to be rather optimistic, given that the observed effect sizes for the primary outcomes were much lower than expected (TAS20-F2 scores: d = -0.57; ASD-Q attitude scores: d = 0.59). Therefore, further differences between the two groups may not have been detected in the present study. The sample size for a larger randomized clinical trial is calculated on the basis of the effect sizes of the changes in TAS20-F2 scores (d = -0.57) and ASD-Q attitude scores (d = 0.59) during the intervention period. To detect a mean difference with a two-sided significance level of 5% and power of 80% with equal allocation to the two arms, this study would require between 47 and 50 participants in each arm of the trial. Although a larger sample could have been used to increase power of the between-group effects, the sample size was defined prior to the start of the study based on the initial power calculation and this could not be altered retrospectively.

This study has several limitations. First, the use of a waitlist control group limits the interpretation of the findings; therefore, it remains unclear which aspects of the CBT program are associated with changes in emotion regulation. Future studies should use more active control conditions (e.g., a group that does not include psychoeducation about ASD and emotion regulation) to delineate the active ingredients of the CBT program more precisely. Second, the assessments of improved outcomes were measured using self-report methods. Therefore, the placebo effect may have affected the results. Future studies should assess these components using blinded assessments.

In conclusion, our study provides preliminary evidence of the efficacy of the group-based CBT program on emotion regulation in autistic adults, thereby supporting a further evaluation of its effectiveness in a larger randomized clinical trial. However, the modest and inconsistent effects underscore the importance of continued efforts to improve the CBT program beyond current standards.

Supporting information

S1 File. CONSORT checklist.

(PDF)

S2 File. ASD knowledge and attitude quiz.

(PDF)

S3 File. Study protocol.

(PDF)

S4 File. Study protocol Japanese version.

(PDF)

S5 File. Minimal underlying data set.

(XLSX)

Data Availability

All relevant data are within the paper and its Supporting information files.

Funding Statement

This study was supported by an Intramural Research Grant (23–1) from the Neurological and Psychiatric Disorders program of the National Center of Neurology and Psychiatry and Grants-in-Aid (No. 23119706 and No. 22531078). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Joshi G, Petty C, Wozniak J, Henin A, Fried R, Galdo M, et al. The heavy burden of psychiatric comorbidity in youth with autism spectrum disorders: a large comparative study of a psychiatrically referred population. J Autism Dev Disord. 2010;40(11): 1361–1370. doi: 10.1007/s10803-010-0996-9 [DOI] [PubMed] [Google Scholar]
  • 2.Lugnegård T, Hallerbäck MU, Gillberg C. Psychiatric comorbidity in young adults with a clinical diagnosis of Asperger syndrome. Res Dev Disabil. 2011;32(5): 1910–1917. doi: 10.1016/j.ridd.2011.03.025 [DOI] [PubMed] [Google Scholar]
  • 3.Croen LA, Zerbo O, Qian Y, Massolo ML, Rich S, Sidney S, et al. The health status of adults on the autism spectrum. Autism. 2015;19(7): 814–823. doi: 10.1177/1362361315577517 [DOI] [PubMed] [Google Scholar]
  • 4.Lord C, Elsabbagh M, Baird G, Veenstra-Vanderweele J. Autism spectrum disorder. Lancet. 2018;392(10146): 508–520. doi: 10.1016/S0140-6736(18)31129-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Gotham K, Brunwasser SM, Lord C. Depressive and anxiety symptom trajectories from school age through young adulthood in samples with autism spectrum disorder and developmental delay. J Am Acad Child Adolesc Psychiatry. 2015;54(5): 369–376.e3. doi: 10.1016/j.jaac.2015.02.005 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.White SW, Roberson-Nay R. Anxiety, social deficits, and loneliness in youth with autism spectrum disorders. J Autism Dev Disord. 2009;39(7): 1006–1013. doi: 10.1007/s10803-009-0713-8 [DOI] [PubMed] [Google Scholar]
  • 7.Weiss JA, Thomson K, Chan L. A systematic literature review of emotion regulation measurement in individuals with autism spectrum disorder. Autism Res. 2014;7(6): 629–648. doi: 10.1002/aur.1426 [DOI] [PubMed] [Google Scholar]
  • 8.White SW, Mazefsky CA, Dichter GS, Chiu PH, Richey JA, Ollendick TH. Social-cognitive, physiological, and neural mechanisms underlying emotion regulation impairments: understanding anxiety in autism spectrum disorder. Int J Dev Neurosci. 2014;39: 22–36. doi: 10.1016/j.ijdevneu.2014.05.012 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Cai RY, Richdale AL, Uljarević M, Dissanayake C, Samson AC. Emotion regulation in autism spectrum disorder: where we are and where we need to go. Autism Res. 2018;11(7): 962–978. doi: 10.1002/aur.1968 [DOI] [PubMed] [Google Scholar]
  • 10.Eisenberg N, Spinrad TL. Emotion-related regulation: sharpening the definition. Child Dev. 2004;75(2): 334–339. doi: 10.1111/j.1467-8624.2004.00674.x [DOI] [PubMed] [Google Scholar]
  • 11.Gyurak A, Gross JJ, Etkin A. Explicit and implicit emotion regulation: a dual-process framework. Cogn Emot. 2011;25(3): 400–412. doi: 10.1080/02699931.2010.544160 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Swain D, Scarpa A, White S, Laugeson E. Emotion dysregulation and anxiety in adults with ASD: does social motivation play a role? J Autism Dev Disord. 2015;45(12): 3971–3977. doi: 10.1007/s10803-015-2567-6 [DOI] [PubMed] [Google Scholar]
  • 13.Cai RY, Richdale AL, Dissanayake C, Uljarević M. Brief report: inter-relationship between emotion regulation, intolerance of uncertainty, anxiety, and depression in youth with autism spectrum disorder. J Autism Dev Disord. 2018;48(1): 316–325. doi: 10.1007/s10803-017-3318-7 [DOI] [PubMed] [Google Scholar]
  • 14.Samson AC, Huber O, Gross JJ. Emotion regulation in Asperger’s syndrome and high-functioning autism. Emotion. 2012;12(4): 659–665. doi: 10.1037/a0027975 [DOI] [PubMed] [Google Scholar]
  • 15.Sheppes G, Suri G, Gross JJ. Emotion regulation and psychopathology. Annu Rev Clin Psychol. 2015;11: 379–405. doi: 10.1146/annurev-clinpsy-032814-112739 [DOI] [PubMed] [Google Scholar]
  • 16.Tani P, Lindberg N, Joukamaa M, Nieminen-von Wendt T, von Wendt L, Appelberg B, et al. Asperger syndrome, alexithymia and perception of sleep. Neuropsychobiology. 2004;49(2): 64–70. doi: 10.1159/000076412 [DOI] [PubMed] [Google Scholar]
  • 17.Baron-Cohen S, Leslie AM, Frith U. Does the autistic child have a “theory of mind”? Cognition. 1985;21(1): 37–46. doi: 10.1016/0010-0277(85)90022-8 [DOI] [PubMed] [Google Scholar]
  • 18.Cantio C, Jepsen JR, Madsen GF, Bilenberg N, White SJ. Exploring “The autisms” at a cognitive level. Autism Res. 2016;9(12): 1328–1339. doi: 10.1002/aur.1630 [DOI] [PubMed] [Google Scholar]
  • 19.Happe F, Cook JL, Bird G. The structure of social cognition: In(ter)dependence of sociocognitive processes. Annu Rev Psychol. 2017;68: 243–267. doi: 10.1146/annurev-psych-010416-044046 [DOI] [PubMed] [Google Scholar]
  • 20.Livingston LA, Happe F. Conceptualising compensation in neurodevelopmental disorders: Reflections from autism spectrum disorder. Neurosci Biobehav Rev. 2017;80: 729–742. doi: 10.1016/j.neubiorev.2017.06.005 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Brewer R, Happe F, Cook R, Bird G. Commentary on "Autism, oxytocin and interoception": Alexithymia, not Autism Spectrum Disorders, is the consequence of interoceptive failure. Neurosci Biobehav Rev. 2015;56: 348–353. doi: 10.1016/j.neubiorev.2015.07.006 [DOI] [PubMed] [Google Scholar]
  • 22.Moriguchi Y, Ohnishi T, Lane RD, Maeda M, Mori T, Nemoto K, et al. Impaired self-awareness and theory of mind: an fMRI study of mentalizing in alexithymia. Neuroimage. 2006;32(3): 1472–1482. doi: 10.1016/j.neuroimage.2006.04.186 [DOI] [PubMed] [Google Scholar]
  • 23.Sofronoff K, Attwood T, Hinton S. A randomised controlled trial of a CBT intervention for anxiety in children with Asperger syndrome. J Child Psychol Psychiatry. 2005;46(11): 1152–1160. doi: 10.1111/j.1469-7610.2005.00411.x [DOI] [PubMed] [Google Scholar]
  • 24.White SW, Ollendick T, Albano AM, Oswald D, Johnson C, Southam-Gerow MA, et al. Randomized controlled trial: multimodal Anxiety and Social Skill Intervention for adolescents with autism spectrum disorder. J Autism Dev Disord. 2013;43(2):382–94. doi: 10.1007/s10803-012-1577-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.White SW, Ollendick T, Scahill L, Oswald D, Albano AM. Preliminary efficacy of a cognitive-behavioral treatment program for anxious youth with autism spectrum disorders. J Autism Dev Disord. 2009;39(12): 1652–1662. doi: 10.1007/s10803-009-0801-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Sukhodolsky DG, Bloch MH, Panza KE, Reichow B. Cognitive-behavioral therapy for anxiety in children with high-functioning autism: a meta-analysis. Pediatrics. 2013;132(5): e1341–50. doi: 10.1542/peds.2013-1193 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Sofronoff K, Attwood T, Hinton S, Levin I. A randomized controlled trial of a cognitive behavioural intervention for anger management in children diagnosed with Asperger syndrome. J Autism Dev Disord. 2007;37(7): 1203–1214. doi: 10.1007/s10803-006-0262-3 [DOI] [PubMed] [Google Scholar]
  • 28.Scarpa A, Reyes NM. Improving emotion regulation with CBT in young children with high functioning autism spectrum disorders: a pilot study. Behav Cogn Psychother. 2011;39(4): 495–500. doi: 10.1017/S1352465811000063 [DOI] [PubMed] [Google Scholar]
  • 29.Thomson K, Burnham Riosa P, Weiss JA. Brief report of preliminary outcomes of an emotion regulation intervention for children with autism spectrum disorder. J Autism Dev Disord. 2015;45(11): 3487–3495. doi: 10.1007/s10803-015-2446-1 [DOI] [PubMed] [Google Scholar]
  • 30.Weiss JA, Thomson K, Burnham Riosa P, Albaum C, Chan V, Maughan A, et al. A randomized waitlist-controlled trial of cognitive behavior therapy to improve emotion regulation in children with autism. J Child Psychol Psychiatry. 2018;59(11): 1180–1191. doi: 10.1111/jcpp.12915 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Russell AJ, Jassi A, Fullana MA, Mack H, Johnston K, Heyman I, et al. Cognitive behavior therapy for comorbid obsessive–compulsive disorder in high-functioning autism spectrum disorders: a randomized controlled trial. Depress Anxiety. 2013;30(8): 697–708. doi: 10.1002/da.22053 [DOI] [PubMed] [Google Scholar]
  • 32.Jutel A, Nettleton S. Towards a sociology of diagnosis: reflections and opportunities. Soc Sci Med. 2011;73(6): 793–800. doi: 10.1016/j.socscimed.2011.07.014 [DOI] [PubMed] [Google Scholar]
  • 33.Kuroda M, Kawakubo Y, Kuwabara H, Yokoyama K, Kano Y, Kamio Y. A cognitive-behavioral intervention for emotion regulation in adults with high-functioning autism spectrum disorders: study protocol for a randomized controlled trial. Trials. 2013;14: 231. doi: 10.1186/1745-6215-14-231 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.American Psychiatric Association. Diagnostic and statistical manual of mental disorders, fourth edition, text revision. Washington, DC: American Psychiatric Association; 2000. [Google Scholar]
  • 35.Lord C, Rutter M, Dilavore P, Risi S. ADOS manual. Los Angeles: Western Psychological Services; 2000. [Google Scholar]
  • 36.Tsuchiya KJ, Matsumoto K, Yagi A, Inada N, Kuroda M, Inokuchi E, et al. Reliability and validity of autism diagnostic interview-revised, Japanese version. J Autism Dev Disord. 2013;43(3): 643–662. doi: 10.1007/s10803-012-1606-9 [DOI] [PubMed] [Google Scholar]
  • 37.Wakabayashi A, Baron-Cohen S, Wheelwright S, Tojo Y. The Autism-Spectrum Quotient (AQ) in Japan: A cross-cultural comparison. J Autism Dev Disord. 2006;36(2): 263–270. doi: 10.1007/s10803-005-0061-2 [DOI] [PubMed] [Google Scholar]
  • 38.Takei R, Matsuo J, Takahashi H, Uchiyama T, Kunugi H, Kamio Y. Verification of the utility of the social responsiveness scale for adults in non-clinical and clinical adult populations in Japan. BMC Psychiatry. 2014;14(1): 302. doi: 10.1186/s12888-014-0302-z [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Kuroda M, Inada N, Uchiyama T. A Japanese version of the SCQ. Tokyo: Kaneko Publisher; 2013. [Google Scholar]
  • 40.Wakabayashi A, Baron-Cohen S, Uchiyama T, Yoshida Y, Kuroda M, Wheelwright S. Empathizing and systemizing in adults with and without autism spectrum conditions: cross-cultural stability. J Autism Dev Disord. 2007;37(10): 1823–1832. doi: 10.1007/s10803-006-0316-6 [DOI] [PubMed] [Google Scholar]
  • 41.Fujita K, Maekawa H, Dairoku K, Yamanaka K. A Japanese version of the WAIS-III. Tokyo: Nihon Bunka Kagakusha; 2006. [Google Scholar]
  • 42.Otsubo T, Tanaka K, Koda R, Shinoda J, Sano N, Tanaka S, et al. Reliability and validity of Japanese version of the Mini-International Neuropsychiatric Interview. Psychiatry Clin Neurosci. 2005;59(5): 517–526. doi: 10.1111/j.1440-1819.2005.01408.x [DOI] [PubMed] [Google Scholar]
  • 43.Faul F, Erdfelder E, Lang AG, Buchner A. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods. 2007;39(2): 175–191. doi: 10.3758/BF03193146 [DOI] [PubMed] [Google Scholar]
  • 44.Haramaki T, Shigematsu K. The cognitive affective training-kit (the cat-kit) Japanese version. Saga, JP: A Village Inc.; 2009. [Google Scholar]
  • 45.Attwood T, Callesen K, Nielsen A. The cognitive affective training-kit (the cat-kit). Arlington, TX: Future Horizons Inc.; 2009. [Google Scholar]
  • 46.Yokoyama K, Furukawa T, Watanabe K. Japanese version of CISS. Tokyo: Kaneko Publisher; 2013. [Google Scholar]
  • 47.Moriguchi Y, Maeda M, Igarashi T, Ishikawa T, Shoji M, Kubo C, et al. Age and gender effect on alexithymia in large, Japanese community and clinical samples: a cross-validation study of the Toronto alexithymia Scale (TAS-20). Biopsychosoc Med. 2007;1: 7. doi: 10.1186/1751-0759-1-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Wakabayashi A, Katsumata A. The motion picture mind-reading test: Measuring individual differences of social cognitive ability in a young adult population in Japan. J Individ Differ. 2011;32(2): 55–64. doi: 10.1027/1614-0001/a000034 [DOI] [Google Scholar]
  • 49.Rieffe C, De Bruine M, De Rooij M, Stockmann L. Approach and avoidant emotion regulation prevent depressive symptoms in children with an Autism Spectrum Disorder. Int J Dev Neurosci. 2014;39: 37–43. doi: 10.1016/j.ijdevneu.2014.06.003 [DOI] [PubMed] [Google Scholar]
  • 50.Tazaki M, Nakane Y. The Japanese version of WHOQOL26. Tokyo: Kaneko Publisher; 2008. [Google Scholar]
  • 51.Asakura S, Inoue S, Sasaki F, Sasaki Y, Kitagawa N, Inoue T, et al. Reliability and validity of the Japanese version of the Liebowitz Social Anxiety Scale. Seishin Igaku. 2002;44: 1077–1084. [Google Scholar]
  • 52.Suzuki T, Tsukamoto K, Abe K. Characteristics factor structures of the Japanese version of the State–Trait Anxiety Inventory: coexistence of positive-negative and state-trait factor structures. J Pers Assess. 2000;74(3): 447–458. doi: 10.1207/S15327752JPA7403_8 [DOI] [PubMed] [Google Scholar]
  • 53.Okajima I, Kanai Y, Sasagawa T, Kanazawa J, Akita K, Chen J, et al. The development of Social Phobia and Anxiety Inventory Japanese version. Jpn J Behav Ther. 2008;34(3): 297–309. [Google Scholar]
  • 54.Shima S. Japanese version of NIMH/CES-D. Tokyo: Chiba Test Center; 1998. [Google Scholar]
  • 55.Bagby RM, Taylor GJ, Parker JD. The twenty-item Toronto alexithymia scale—II. Convergent, discriminant, and concurrent validity. J Psychosom Res. 1994;38(1): 33–40. doi: 10.1016/0022-3999(94)90006-x [DOI] [PubMed] [Google Scholar]
  • 56.Gordon K, Murin M, Baykaner O, Roughan L, Livermore-Hardy V, Skuse D, et al. A randomised controlled trial of PEGASUS, a psychoeducational programme for young people with high-functioning autism spectrum disorder. J Child Psychol Psychiatry. 2015;56(4): 468–476. doi: 10.1111/jcpp.12304 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57.Smith LE, Greenberg JS, Mailick MR. Adults with autism: outcomes, family effects, and the multi-family group psychoeducation model. Curr Psychiatry Rep. 2012;14(6): 732–738. doi: 10.1007/s11920-012-0328-1 [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Valsamma Eapen

23 Aug 2021

PONE-D-21-17599

Preliminary efficacy of cognitive behavioral therapy on emotion regulation in adults with autism spectrum disorder: a pilot randomized waitlist-controlled study

PLOS ONE

Dear Dr. Kuwabara,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Oct 07 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Valsamma Eapen, MBBS, PhD, FRCPsych, FRANZCP

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Thank you for stating the following financial disclosure: 

This study was supported by an Intramural Research Grant (23–1) from the Neurological and Psychiatric Disorders program of the National Center of Neurology and Psychiatry and Grants-in-Aid (No. 23119706 and No. 22531078).

Please state what role the funders took in the study.  If the funders had no role, please state: "The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript." 

If this statement is not correct you must amend it as needed. 

Please include this amended Role of Funder statement in your cover letter; we will change the online submission form on your behalf.

3. In your Data Availability statement, you have not specified where the minimal data set underlying the results described in your manuscript can be found. PLOS defines a study's minimal data set as the underlying data used to reach the conclusions drawn in the manuscript and any additional data required to replicate the reported study findings in their entirety. All PLOS journals require that the minimal data set be made fully available. For more information about our data policy, please see http://journals.plos.org/plosone/s/data-availability.

Upon re-submitting your revised manuscript, please upload your study’s minimal underlying data set as either Supporting Information files or to a stable, public repository and include the relevant URLs, DOIs, or accession numbers within your revised cover letter. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories. Any potentially identifying patient information must be fully anonymized.

Important: If there are ethical or legal restrictions to sharing your data publicly, please explain these restrictions in detail. Please see our guidelines for more information on what we consider unacceptable restrictions to publicly sharing data: http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. Note that it is not acceptable for the authors to be the sole named individuals responsible for ensuring data access.

We will update your Data Availability statement to reflect the information you provide in your cover letter.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Partly

Reviewer #2: No

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: No

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The manuscript entitled ‘Preliminary efficacy of cognitive behavioral therapy on emotion regulation in adults with

autism spectrum disorder: a pilot randomized waitlist-controlled study’ with the aim to explore the preliminary efficacy of CBT on emotion regulation in adults with ASD.

Comments

Materials and Methods

Line 12, 15, 135-137, the time period Week 0-4, Week 4-8, Week 20 could be used to indicate the time period of assessment at pre, post and follow up.

Statistical analyses

Line 148, one or 2 tailed test to be stated.

If inferential statistics/p value is used/determined for the pilot study, at least sample size calculation could be added even though the study was an exploration. Likewise with repeated measure statistical test and multiple comparison correction.

The strength/findings of Cohen's d to be highlighted/discussed.

Results

Table 2, the decimal points for the p values to be standardized. Nonetheless, based on CONSORT statement, all statistical analyses for baseline comparison to be avoided.

Missing data to be stated if any.

Line 320-330, table to be cited.

Figure 1, the period of assessment to be incorporated in

List of references to follow PLoS ONE format.

Reviewer #2: Thank you for the opportunity to review this paper which conducted a randomised clinical trial exploring a CBT program intervention in autistic adults. I feel that some very good work was done, though overall that the largely non-significant results do not support the framing of the discussion of conclusions. My specific comments as follows:

Stylistic issue, I do prefer identity first language and note the general shift in many academic autism literature to identity first given the stated preferences of the autistic adult community. Though this is a decision for the authors and editor.

The statement “Moreover, the implementation of prominent emotion regulation strategy patterns in ASD has been associated with mental disorders” is unclear to me, I suggest it needs more explanation.

I would suggest the reference to theory of mind in the introduction is overly simplistic, and does not capture the controversy and latest research regarding the claim of theory of mind impairment in autistic adults.

The inclusion criteria of “All participants needed to have an awareness of their lack of emotional self-awareness” seems vague to me, how was this assessed?

I feel the ASD Quiz might be better named along the lines of an autism knowledge and attitude quiz to make it easier for the reader to follow.

I would suggest a paragraph break before describing the TAS20 would improve readability.

I feel the discussion also needs to open describing the general lack of change across the majority of measures. Overall, I think that, although more work and research is needed, the discussion needs to be forthcoming in suggesting that there may only minimal value in CBT for autistic adults based on findings in this study. I suggest perhaps the authors engage with grey literature from autistic adults who are critical of CBT approaches to help contextualise why these findings may occur. I am not sure entirely of the conclusion being made given the generally non-significant results.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2022 Nov 23;17(11):e0277398. doi: 10.1371/journal.pone.0277398.r002

Author response to Decision Letter 0


30 Sep 2021

We would like to thank the Reviewers for their insightful comments and suggestions, which we believe have helped us improve our manuscript and provide a more balanced account of our research. We have carefully reviewed our manuscript according to their comments and made the necessary changes, which have been tracked in the revised manuscript to facilitate the review process. Please find below our point-by-point responses to all comments.

Reviewer #1:

Line 12, 15, 135-137, the time period Week 0-4, Week 4-8, Week 20 could be used to indicate the time period of assessment at pre, post and follow up.

Response: We would like to thank you for your valuable suggestion, we have now revised our manuscript accordingly. (Page 4, Lines: 12-13, 16; Page 11, Lines: 141-142, 143)

Line 148, one or 2 tailed test to be stated.

Response: We would like to thank you for your comment and apologize for the lack of clarity, we have now revised our manuscript accordingly. (Page 12, Line 154)

If inferential statistics/p value is used/determined for the pilot study, at least sample size calculation could be added even though the study was an exploration. Likewise with repeated measure statistical test and multiple comparison correction.

Response: We would like to thank you for your insightful suggestion. We confirm that we have now added the requested information to our revised manuscript as follows:

“The sample size for a larger randomized clinical trial is calculated on the basis of the effect sizes of the changes in TAS20-F2 scores (d = -0.57) and ASD-Q attitude scores (d = 0.59) during the intervention period. To detect a mean difference with a two-sided significance level of 5% and power of 80% with equal allocation to the two arms, this study would require 47-50 participants in each arm of the trial.” (Page 29, Lines: 412-416)

“Additionally, we conducted a repeated measure analysis of variance to explore the changes in the three outcomes over time, which showed significant results in the t-tests (i.e., TAS20-F2, ASD-Q attitude, and CISS-E). Specifically, treatment group (i.e., the CBT vs WL control group) was considered as the between-subjects factor, while time point (i.e., pre-intervention, post-intervention, and follow-up) as the within-subjects factor. With respect to the TAS20-F2 scores, a significant effect of treatment group was found (F = 5.81, p = 0.19), whereas we did not observe a main effect of time (F = 1.33, p = 0.27) or a group-by-time interaction (F = 1.57, p = 0.22). With regards to the ASD-Q attitude scores, a group-by-time interaction and a main effect of treatment group or time were not seen (F = 3.03, p = 0.05; F = 0.05, p = 0.82; F = 0.65, p = 0.52, respectively). Finally, with respect to the CISS-E, a significant effect of time was found (F = 4.69, p = 0.02), whereas we did not observe a group-by-time interaction (F=3.23, p = 0.05) or a main effect of treatment group (F = 0.03, p = 0.86).” (Page 25, Lines: 336-348)

“This being said, these findings did not withstand the Bonferroni correction for multiple comparisons for the 10 primary outcome measures (p < 0.05/10).” (Page 22, Lines: 303-304)

The strength/findings of Cohen’s d to be highlighted/discussed.

Response: We would like to thank you for your insightful comment and apologize for the lack of information. We confirm that we have now added the following sentences to the “Discussion” section of our revised manuscript to increase clarity:

“The initial power calculation proved to be rather optimistic, given that the observed effect sizes for the primary outcomes were much lower than expected (TAS20-F2 scores; d = -0.57 and ASD-Q attitude scores; d = 0.59). Therefore, further differences between the two groups may have not been detected in the present study. Although a larger sample could have been used to increase the power of the between-group effects, the sample size was defined prior to the start of the study based on the initial power calculation and this could not be altered in retrospect.” (Page 28, Lines: 394-400)

Table 2, the decimal points for the p values to be standardized. Nonetheless, based on CONSORT statement, all statistical analyses for baseline comparison to be avoided.

Response: We would like to thank you for your comment. We have now deleted all statistical analyses for baseline comparison from our revised manuscript, as suggested.

Missing data to be stated if any.

Response: We would like to thank you for your valuable comment. We have now states the above in the annotation of Table 2. (Page 21, Line 289)

Line 320-330, table to be cited.

Response: We would like to thank you for your valuable comment. We are pleased to inform you that our manuscript has now been revised accordingly. (Page 24, Line 324)

Figure 1, the period of assessment to be incorporated in

Response: We would like to thank you for your comment. We have now revised Figure 1 according to your suggestion.

List of references to follow PLoS ONE format.

Response: We would like to thank you for your valuable comment and apologize for the mistake. We have now revised the List of References according to the PLOS ONE ‘s style requirements.

Reviewer #2:

Stylistic issue, I do prefer identity first language and note the general shift in many academic autism literature to identity first given the stated preferences of the autistic adult community. Though this is a decision for the authors and editor.

Response: We would like to thank you for your insightful comment. We confirm that we have now changed the description to identity first language throughout our revised manuscript to address your comment.

The statement “Moreover, the implementation of prominent emotion regulation strategy patterns in ASD has been associated with mental disorders” is unclear to me, I suggest it needs more explanation.

Response: We would like to thank you for your insightful comment and apologize for the lack of clarity. We have now noticed that the meaning of the mentioned statement overlapped with the previous sentence (Page 5, Line 33), ”Studies on emotion regulation in both children and ASD adults have primarily focused on differences in the implementation of particular emotion regulation strategy, in addition to the relationship between particular emotion regulation and a range of outcomes, including mental health and social functioning”. Therefore we have now deleted the mentioned statement from our revised manuscript to increase accuracy.

I would suggest the reference to theory of mind in the introduction is overly simplistic, and does not capture the controversy and latest research regarding the claim of theory of mind impairment in autistic adults.

Response: We would like to thank you for your valuable suggestion. We have now added the following sentences to the “Introduction” section of our revised manuscript to increase clarity:

“Theory of mind, i.e., the ability to attribute mental states to others to make sense of their behavior, has been previously suggested to be atypical in ASD [18, 19]. However, it remains unknown whether a universal pattern of cognitive impairment in ASD exists and whether multiple cognitive impairments are needed to explain its full range of behavioral symptoms [20]. Social cognition clearly encompasses a range of processes, including, but not limited to, theory of mind and emotion processing, which appear to be distinct but interdependent [21].” (Page 6, Line 54; Page 7, Lines: 55-61)

As a consequence, the following references were added to our revised Reference List:

18. Cantio C, Jepsen JR, Madsen GF, Bilenberg N, White SJ. Exploring 'The autisms' at a cognitive level. Autism Res. 2016;9(12):1328-39. doi: 10.1002/aur.1630.

19. Happe F, Cook JL, Bird G. The Structure of Social Cognition: In(ter)dependence of Sociocognitive Processes. Annu Rev Psychol. 2017;68:243-67. doi: 10.1146/annurev-psych-010416-044046.

20. Livingston LA, Happe F. Conceptualising compensation in neurodevelopmental disorders: Reflections from autism spectrum disorder. Neurosci Biobehav Rev. 2017;80:729-42. doi: 10.1016/j.neubiorev.2017.06.005.

21. Brewer R, Happe F, Cook R, Bird G. Commentary on "Autism, oxytocin and interoception": Alexithymia, not Autism Spectrum Disorders, is the consequence of interoceptive failure. Neurosci Biobehav Rev. 2015;56:348-53. doi: 10.1016/j.neubiorev.2015.07.006.

The inclusion criteria of “All participants needed to have an awareness of their lack of emotional self-awareness” seems vague to me, how was this assessed?

Response: We would like to thank you for your valuable comment and apologize for the lack of clarity. Participants’ awareness was assessed through direct interview with a trained psychologists. We have now added the following sentences to the “Materials and methods” section of our revised manuscript to increase understanding:

“Participants’ awareness of their lack of emotional self-awareness and poor comprehension of others’ emotions was confirmed through a direct interview with a PhD-qualified psychologist.” (Page 11, Lines: 128-130)

I feel the ASD Quiz might be better named along the lines of an autism knowledge and attitude quiz to make it easier for the reader to follow.

Response: We would like to thank you for your insightful suggestion. We have now revised the title of the ASD Quiz to “ASD knowledge and attitude quiz.” (Page 15, Line 202; Page 30, Line 423, Supporting information S2 File)

I would suggest a paragraph break before describing the TAS20 would improve readability.

Response: We would like to thank you for your valuable comment. We have now revised our manuscript accordingly. (Page 16, Line 215).

I feel the discussion also needs to open describing the general lack of change across the majority of measures. Overall, I think that, although more work and research is needed, the discussion needs to be forthcoming in suggesting that there may only minimal value in CBT for autistic adults based on findings in this study. I suggest perhaps the authors engage with grey literature from autistic adults who are critical of CBT approaches to help contextualise why these findings may occur. I am not sure entirely of the conclusion being made given the generally non-significant results.

Response: We would like to thank you for your insightful comment. We have now added the following explanation of the limited significance in the differences between groups to the “Discussion” section of our revised manuscript to increase accuracy:

“The initial power calculation proved to be rather optimistic, given that the observed effect sizes for the primary outcomes were much lower than expected (TAS20-F2 scores; d = -0.57 and ASD-Q attitude scores; d = 0.59). Therefore, further differences between the two groups may have not been detected in the present study. Although a larger sample could have been used to increase the power of the between-group effects, the sample size was defined prior to the start of the study based on the initial power calculation and could not be altered in retrospect.” (Page 28, Lines: 394-400)

Attachment

Submitted filename: Response to Reviewers.docx

Decision Letter 1

Tarek K Rajji

4 Jul 2022

PONE-D-21-17599R1Preliminary efficacy of cognitive behavioral therapy on emotion regulation in autism spectrum disorder adults: a pilot randomized waitlist-controlled studyPLOS ONE

Dear Dr. Kuwabara,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

 While the changes require a major revision, I believe they can be reasonably addressed.

Please submit your revised manuscript by Aug 18 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Tarek K Rajji

Academic Editor

PLOS ONE

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: (No Response)

Reviewer #2: (No Response)

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Partly

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: No

Reviewer #2: No

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: (No Response)

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The authors have put in great effort to address the comments.

Minor comment(s)

Line 335, Repeated measures ANOVA comes with pairwise/multiple comparison for post hoc test. If based on repeated measures ANOVA approach, the use of t test to be clarified in the text.

Reviewer #2: Thank you for the opportunity to again review this manuscript. I still feel the discussion and abstract needs to be more forthcoming describing the general lack of change across the majority of measures. Overall, I think that, although more work and research is needed, the discussion needs to be cautious in suggesting that there may only minimal value in group CBT for autistic adults based on findings in this study.

An additional outstanding concern is the use of language. When I refer to identity first, I mean using the term “autistic adult” not “ASD adult” or “ASD individual”. Alternatively neutral language, which you could perhaps use at the start of the introduction, would be “Adults on the autism spectrum”. Also I think it’s better to refer to autism generally after an initial first mention of ASD.

Just checking if it should be an ‘or’ not an ‘and’ in the list of tools used in diagnostic confirmation?

In the analyses section you say no adjustment was made for multiple comparisons, then in results a Bonferroni correction is described?

Significance is unclear to me when it is reported “With 356 respect to the TAS20-F2 scores, a significant effect of treatment group was found (F = 5.81, p = 0.19)” given the p value?

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2022 Nov 23;17(11):e0277398. doi: 10.1371/journal.pone.0277398.r004

Author response to Decision Letter 1


5 Aug 2022

We would like to thank the reviewers for their insightful comments and suggestions, which have helped us improve our manuscript and provide a more balanced account of our research. We have carefully reviewed our manuscript in light of their comments and made the necessary changes, which are shown in red font in the revised manuscript to facilitate the review process. Please find below our point-by-point responses to their comments.

Reviewer #1

Line 335, Repeated measures ANOVA comes with pairwise/multiple comparison for post hoc test. If based on repeated measures ANOVA approach, the use of t test to be clarified in the text.

Response: Thank you for your valuable suggestion. We have revised our manuscript accordingly (page 21, line 305; page 24, line 333).

Reviewer #2

I still feel the discussion and abstract needs to be more forthcoming describing the general lack of change across the majority of measures. Overall, I think that, although more work and research is needed, the discussion needs to be cautious in suggesting that there may only minimal value in group CBT for autistic adults based on findings in this study.

Response: Thank you for your insightful comment. We have revised the discussion section (page 28, lines 405-407), and added the following explanation of the general lack of differences between groups to both the discussion section and the abstract of our revised manuscript to be more forthcoming:

“However, the modest and inconsistent effects underscore the importance of continued efforts to improve the CBT program program beyond current standards” (page 4, lines 23-24; pages 28-29, lines 421-423).

An additional outstanding concern is the use of language. When I refer to identity first, I mean using the term “autistic adult” not “ASD adult” or “ASD individual”. Alternatively neutral language, which you could perhaps use at the start of the introduction, would be “Adults on the autism spectrum”. Also I think it’s better to refer to autism generally after an initial first mention of ASD.

Response: Thank you for this valuable comment. In response to your comment, we changed the description to “autistic” instead of “ASD” throughout our revised manuscript.

Just checking if it should be an ‘or’ not an ‘and’ in the list of tools used in diagnostic confirmation?

Response: We apologize for the mistake. It should be “or”. We have revised the manuscript accordingly (page 9, line 126).

In the analyses section you say no adjustment was made for multiple comparisons, then in results a Bonferroni correction is described?

Response: We appreciate your comment. We deleted the following sentence from the analyses section: “We did not conduct a correction for the multiple comparisons due to the exploratory nature of this study.”

Significance is unclear to me when it is reported “With 356 respect to the TAS20-F2 scores, a significant effect of treatment group was found (F = 5.81, p = 0.19)” given the p value?

Response: We apologize for the mistake. It should be “p = 0.019”. We have revised the manuscript accordingly (page 24, line 347).

Attachment

Submitted filename: Response_to_Reviewers.docx

Decision Letter 2

Tarek K Rajji

6 Sep 2022

PONE-D-21-17599R2Preliminary efficacy of cognitive-behavioral therapy on emotion regulation in adults with autism spectrum disorder: a pilot randomized waitlist-controlled studyPLOS ONE

Dear Dr. Kuwabara,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Oct 21 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Tarek K Rajji

Academic Editor

PLOS ONE

Journal Requirements:

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: (No Response)

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: (No Response)

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: (No Response)

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: (No Response)

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: (No Response)

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: (No Response)

Reviewer #2: Thank you for addressing previous suggestions. I noticed - "it remains unclear which aspects of the CBT program are associated with changes in ASD" - I don't believe ASD changes and feel this sentence should be revised.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2022 Nov 23;17(11):e0277398. doi: 10.1371/journal.pone.0277398.r006

Author response to Decision Letter 2


7 Sep 2022

Reviewer #2

Thank you for addressing previous suggestions. I noticed - "it remains unclear which aspects of the CBT program are associated with changes in ASD" - I don't believe ASD changes and feel this sentence should be revised.

Response: We apologize for the mistake. It should be “emotion regulation”. We have revised the manuscript accordingly (page 28, line 413).

Attachment

Submitted filename: Response_to_Reviewers.docx

Decision Letter 3

Tarek K Rajji

27 Oct 2022

Preliminary efficacy of cognitive-behavioral therapy on emotion regulation in adults with autism spectrum disorder: a pilot randomized waitlist-controlled study

PONE-D-21-17599R3

Dear Dr. Kuwabara,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Tarek K Rajji

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Acceptance letter

Tarek K Rajji

15 Nov 2022

PONE-D-21-17599R3

Preliminary efficacy of cognitive-behavioral therapy on emotion regulation in adults with autism spectrum disorder: a pilot randomized waitlist-controlled study

Dear Dr. Kuwabara:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Tarek K Rajji

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 File. CONSORT checklist.

    (PDF)

    S2 File. ASD knowledge and attitude quiz.

    (PDF)

    S3 File. Study protocol.

    (PDF)

    S4 File. Study protocol Japanese version.

    (PDF)

    S5 File. Minimal underlying data set.

    (XLSX)

    Attachment

    Submitted filename: Response to Reviewers.docx

    Attachment

    Submitted filename: Response_to_Reviewers.docx

    Attachment

    Submitted filename: Response_to_Reviewers.docx

    Data Availability Statement

    All relevant data are within the paper and its Supporting information files.


    Articles from PLOS ONE are provided here courtesy of PLOS

    RESOURCES